QuidelOrtho Corp. Hits New 52-Week Low at $16.16 Amid Ongoing Struggles

QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 16.16 as of March 19, 2026. This significant decline marks a staggering 59.7% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance, which has seen a gain of 16.41% during the same period. The company's market capitalization stands at USD 1,202 million, and it has been grappling with financial difficulties, as evidenced by its negative results over the last 12 consecutive quarters. Key financial metrics reveal a debt-equity ratio of 1.31, indicating a higher reliance on debt, while the return on equity is reported at -7.95%. Additionally, the price-to-book ratio is notably low at 0.63, suggesting that the stock may be undervalued relative to its assets. QuidelOrtho's performance has consistently lagged behind the S&P 500 over the last three years, raising concerns about its market position and future viability. The stock's 52-week high was recorded at USD 38.99, highlighting the extent of its recent decline.